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DEAN'S MESSAGE
Dr. G.M.H. Shires, Dean, College of Veterinary Medicine

August 1998
I hope that you enjoy the new format for this annual report. It certainly makes it more
attractive and, I am sure, much more readable. Dr. Potgieter and his staff, along with the
College's Office of Veterinary Medical Communications, put many long hours into this
production . We offer our thanks to them for a job well done .
Once again, the faculty of the Center of Excellence have been most productive and, as
usual, have performed far above the required benchmarks. Many of them have been
invited to present at international meetings as well as national scientific forums.
Careful management of the funds and strict adherence to gUidelines have allowed the
COE to provide quite generous start-up packages for new researchers as well as a
modest amount of money for equipment purchases for several researchers . The return on
the state of Tennessee is investment is still a very good one and it would certainly enhance
our research program if this investment could be increased as the cost of equipment and,
therefore, the cost of doing research, rises every year.
The careful dispensation of the funds from this Center has been instrumental in assisting
new researchers in successfully obtaining extramural funding as well as supporting some
of our established researchers who may have a gap in their external funding. The COE
continues to be the backbone which gives support to our entire research effort and is a
sound investment in relation to funds from external sources .
My thanks to the state of Tennessee for its continuing support of the Center. Thanks also to
the researchers who continue to be so productive and to our research leadership who are
such excellent stewards of the COE. I hope you enjoy this publication.
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PROGRAM REPORT
Dr. Leon N.D. Potgieter, Director of Research and Graduate Programs

I

am pleased to report on an active year for the Center of
Excellence in livestock Diseases and Animal Health in 1997. Once
again the Center has met its objectives admirably. The number of
peer-reviewed scientific publications published by faculty supported
by the Center continues to be truly astounding. These faculty have
presented their work as seminars or as posters at local, regional, na
tional and international scientific meetings and other venues. Research
results are disseminated, not only in prestigious, peer-reviewed interna
tional journals, but also in popular journals and magazines distributed
regionally and nationally. Several of our investigators, such as Drs.
Rouse, Schuller, Brian, Stephen Oliver and Jack Oliver, have been
invited to give keynote presentations at international scientific meet
ings.
The annual report this year has been prepared in a format
different from previous years. We have chosen to focus on the activi
ties and achievements of those individuals and research teams whose
laboratories constitute the core of the Center. These investigators de
serve tremendous credit for bringing recognition to the College of Vet
erinary Medicine, the Institute of Agriculture and the University of Ten
nessee. Furthermore, they continue to ensure that the Center maintains
its strong competitive position and contribute to the fiscal health of our
research environment. This report format emphasizes the strength of
the Center and gives a clearer indication of how it meets its objectives.

Accomplishments
It should be evident from reading the summaries of the labora
tories featured in this report that the Center:
1.
2.
3.
4.
5.

4

Improves the quality of human life by improving animal
health.
Augments livestock disease research capabilities in the
Institute of Agriculture.
Identifies and characterizes laboratory and animal
models of important human diseases.
Studies animal/laboratory models for better understand
ing of human health.
Studies the mechanisms of disease development and
characterizes causative agents of common diseases im
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10.
1 1.

portant to the state of Tennessee.
Improves the capabilities of the College of Veterinary Medi
cine, the College of Agricultural Sciences and Natural Re
sources and the Agricultural Experiment Station to deal with
diseases.
Improves the facilities to enable the College of Veterinary
Medicine to study more effectively infeclious and toxic dis
eases of animals .
praclical infor
Disseminates through the Extension
mation requi
to reduce the incidence of livestock dis
eases .
Develops new strateg ies for the prevention
disease .
Improves facilities and expertise in order to prOVide im
proved
training .
Develops innovative approaches to the treatment of hu
man diseases .

Research Funding
An important goal of the Center of Excellence is to support re
searchers and to promote research by a variety of mechanisms. The
ter of Excellence in livestock Diseases and Human Health emphasizes the
following six specific areas: Infeclious Diseases/Population Medicine, Toxi
cology, Reproduction,
Defense, Molecular Genej'ics, and Carcino
The Center's underlying philosophy is to enhance young (or new)
investigators' capacity to compete for extramural funding and to assist
established researchers to maintain their extra-mural support. The
does not serve as a primary source of research funding for faculty. The
main criteria used for funding proposals include scientifiC merit, likelihood
of leading to extramural funding and relevance to
Center's obiectives.
Proposals are reviewed by the Research and Graduate Programs Advisory
Committee, and has a representative from every department of the Col
by Dr. David Slauson ..
lege of
ry Medicine, chai
The
supported the following proiects over the past year:

1.

2.
3.

4.

Dr. David Bemis: Recombinant Bordetella bronchiseptica
fimbriae as carriers of unrelated antigens .
Dr. Philip Bochsler: Cloning bovine CD 14, a patho
genrecognition receptor.
Dr. David Brian: How two terminal genej'ic structural
elements regulate replication
the coronavirus RNA ge
nome.
Dr. Kevin Hahn: Reversal of cisplatin resistance using
ethacrynic acid: Evaluation in an osteosarcoma animal
model .
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5.

Dr. Alan Mathew: Characterization of mastitis-causing
agents in swi ne.

6.

7.
8.
9.
10.

1 1.

12.

1 3.
14.
15.

Dr. Charmi Mendis-Handagama: Regulation of
mesenchymal cell differentiation into Leydig
in the neo
natal rat testis.
Dr. Joyce Merryman: The role of c:lun amino-terminal
carcinoma of the lung.
kinases in squamous
Dr. Linda Munson: Role of platelet-derived growth fac
tor in endometriosis and endometrial carcinoma.
Dr. Jack Oliver: Vascular cell injury by toxicants of tall
fescue grass.
Dr. Steve Oliver: Characterization of M proteins from
environmental streptococci and evaluation of
role in
the pathogenesis of bovine mastil"is.
Dr. Bart Rohrbach: InvestigO'l'ion of
role of endo
phyte-infected tall fescue as a risk factor for laminitis in the
horse.
Dr. Barry Rouse: Evaluation of the kinetics and the
suppresmechanism by which mouse IL-l 0 induces
sion.
Dr. Hildegard Schuller: Molecular biology of neu
rotransmitter receptors in lung cancer
Dr. Terry Schultz: Structure-activity relationships for skin
sensi'l'izing chemicals: nitrogenous aromatic electrophiles.
Dr. Erby Wilkinson: SCURFY; genetic
identificaand immunobiology.
tion of the

Equipment
Requests from 1 3 investigators for
of equipment were
of
over the past year. The investigators
funded by
benefiting from these Center grants were Drs. David Bemis/Steve Kania,
David Brian, Alan Mathew, C. Mendis-Handagama, Darryl Millis, Jack
Oliver, Stephen Oliver, Barry Rouse, Terry Schultz, Hildegard Schuller,
Hwa-Chain Wang and Dan Ward. Criteria taken into consideration for
allocation of
funds included justification of need,
uipment avail
ability in adjacent laboratories, and the number of investigators who
benefit.

Student Awards
One mechanism by which the Center of Excellence promotes bio
medical research is to provide summer opportunities for veterinary students
to do investigational
in research laboratories of the College of Veteri
Center funded eight requests from first
nary Medicine. This past year
and second-yea students. At
end of the summer, they provided a
summary of their work to
entered into a competition judged by Phi
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Zeta, the veterinary honor society. The program appears to be
very successful; several students presented their findings at notional
scientific meetings, and several manuscripts have been submitted
for publication in peer-reviewed journals .

Personnel Changes
The Center is sure to benefit by the recent recruitment of two
investigators Drs. Hwa-Chain Wong and Joseph Bartges, who
were provided with generous COE start-up funds this post year. Dr.
Wong's expertise is in molecular mechanisms involved in cancer
and Dr. Bartges interest is in animal models of nutritional diseases .
Dr. Edward Schroeder, Director of the Office of Laboratory
Animal Core, retired during the year. We are pleased that this
position was filled promptly by Dr. Dorcas Schaeffer following a
notional search. The College is currently conducting a search to fill
the remaining open laboratory animal veterinarian position .
The Deportment of Animal Science announced that Dr.
Patricio Tithof joined the deportment to fill a position in physiology
in July. Dr. Tithof's research interest is in line with the Center's focus
and we look forward to her participation.
Dr. linda Munson, who hod been supported by the Center
for several years, resigned in August 1997. I hope that in the near
future the College will receive approval to fill her position, in addi
tion to one in the Deportment of Animal Science. These positions
have hod significant research assignments and could improve the
critical moss of the Center of Excellence .

Funding Levels
The toto I fu nd i ng for the Center of Excellence has not
changed significantly. Both extramural and state funds have re
mained steady. The state's investment in the Center of Excellence
in Livestock Diseases and Human Health remains a healthy one;
our extramural funding still is good, in spite of a difficult and very
competitive funding climate .
I am very encouraged in that several faculty this post year
have secured new multi-year funding for COE-related research .
They include:

Dr. Jack Oliver: Reactivity of bovine vasculature to
ergovaline and ergine of toxic toll fescue. From the No
tional Research Initiative of the United States Deportment
of Agriculture. Total award $188,000.

.,
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Dr. Terry Schultz (co-investigator):

role of bio
a va i I a b iii ty i n de t e r min i n g a c c e pta b I eli mits for the
bioremediation of polychlorinated biphenyls. From the
rt
ment
Energy. Total award $44 1

Dr. Hwa-Chain Wang: Pathway leads to apoptosis in SRC
transformed
From the National Cancer Institute (NIH).
Total award $517,500.

Dr. Stephen Oliver: (a) Influence of prepartum intramam
mary infusion
Pirsue or Albacillin on mastitis and lactational
performance of heifers. From Pharmacia and Upjohn Company.
Total award $65,000;
(b) Lactation/Mastitis Research. From the I. Schattner Founda
tion, Inc. Total award $65,000;
(c) Evaluation
specific immune re sponses and protection
during early lactation following immunization during the nonlactating period with
streptococcal antigens. From Pfizer,
Inc. Total award $
,000.
I look forward to another good year for the
of Excelin livestock
and Human Health. I am confident that the
support provided by the Center for some of our promising investigators
will consitute the embryogenesis of established research programs.
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RESEARCH TRAINING
Dr. David Slauson

Dr. David Slauson (center)
with (from left to right)
Dr. Sharon Witonsky,
Dr. Barbara Sheppard,
and Dr. Brian Julio

The College of Veterinary Medicine funds at least ten
positions for Ph.D.-level training of students with a professional
medical degree. Some of these students are based in the De
partment of Pathology (as part of their residency/ Ph.D program),
and some are awarded without restriction . Most of these stu
dents become linked with investigators conducting Center of
Excellence-related research. The presence of this dynamic group
of young investigators significantly bolsters the achievements of
the Center. Faculty benefiting from these graduate students in
clude Drs . Rouse , Schuller, Wilkinson and Potgieter.
In addition, the University of Tennessee College of Vet
erinary Medicine is one of few veterinary colleges to be chosen
as a site for a NIH Institutional Training Grant.
This five-year training grant on the "Molecular
and Cellular Pathobiology of Environmental Dis
ease" is funded through the National Institutes of
Environmental Health Sciences. The grant be
gan in 1995 and is funded through the year
2000; current annual funding is $ 122,968. This
training grant, initiated by Dr. David Slauson, is
centered in the Department of Pathology, but also
involves scientists from other departments, as well
as important collaborators in the life Sciences
Division at the Oak Ridge National Laboratory. Dr. David O.
Slauson, Program Director for the grant and Pathology Depart
ment Head, said that the NIH funds provide stipend support for
three years of advanced research training for DVM graduate
students who already have at least two years of disease-ori
ented residency training. "We are very honored to have been
selected for this important award," Slauson said. "As far as I
know, we are one of only two Colleges of Veterinary Medicine
in the entire country to have such an environmental pathology
training grant." Slauson indicated that the research training spon
sored by this new NIH grant emphasizes basic molecular and
cellular biology of disease, including environmental disease.
"Our purpose here is to produce well-trained individuals who
understand disease at the tissue and whole animal level, as
well as at the most sophisticated edges of contemporary mo
lecular and cellular pathogenesis," Slauson continued. There

9

are currently three DVM graduate students supported by these NIH
funds and working in the laboratories of COE-associated scientists.
The summaries below illustrate the sort of quality individuals
that we have been able to attract to the University of Tennessee with
this NIH Training Grant:

Dr. Barbara Sheppard is working on the Ph.D. degree in
Dr. Hildegard Schuller's Experimental Oncology Laboratory on
a project involving growth regulation of the cells of origin of
small cell lung cancer. Dr. Sheppard received her B.S. degree
in biology from Virginia Polytechnic Institute in 1986 where she
was on the Dean's list for her lost seven consecutive semesters.
Dr. Sheppard then received a M.S. degree in physiology in
1989, also from VPI, and
was awarded her D.V.M. degree
from North Carolina State University in 1993. Dr. Sheppard
was in private practice in Delaware for a year before entering
the Pathology Residency Program at the University of Florida in
1994. Dr. Sheppard came to the University of Tennessee in
1996 to begin her graduate program.

Dr. Brian Jull is working on the Ph.D. degree in Dr. Schuller's
laboratory, pursuing a difficult project that involves defining
metabolic pathways involved in the regulation of growth of
cells that become small cell lung cancer cells. Dr. Jull received
his undergraduate degree in Animal Science cum laude from
the University of Kentucky where he was a consistent member
of the Dean's list. He received his D.V.M. degree summa cum
laude, near the top in his class from the College of Veterinary
Medicine at Auburn University in 1993. Dr. Jull was in private
practice in Kentucky before joining the pathology residency
training program at the University of Tennessee in 1995. Dr.
Jull was appointed to the NIH training grant in 1997.

Dr. Sharon Witonsky is working in Dr. Erby Wilkinson's
Cellular Pathobiology Laboratory on projects involving mouse
models of genetic diseases. Dr. Witonsky was a Phi Beta Kappa
undergraduate in biology and chemistry at Earlham College,
and received her D.V.M. degree from the University of Minne
sota in 1993 where she was an outstanding student. She came
to UTCVM in 1993 as a graduate student, and has been en
gaged in research as well asclinical training in internal medi
cine here, aiming at specialty board certification and a Ph.D.
degree in Comparative and Experimental Medicine. Dr.
Witonsky was appointed as an NIH Postdoctoral Fellow in
1997.

10

"We believe that the graduates of this program will be able to
contribute to an enhanced understanding of the environmentally-caused
disorders of man and animals," said Dr. Slauson," both in terms of the
morphologic expressions of disease and in terms of its molecular and
cellular pathogenesis. "With trainees of this quality coming out of the
University of Tennessee, College of Veterinary Medicine, we can all
be rather proud," said Dr. Slauson.
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INFLAMMATION
LABORATORY
Dr. Philip N. Bochsier
Fellows and staff: Dr. Z. Yang, Dr. Gary L. Mason

Pneumonia, mastitis, and enteritis/diarrhea of newborns
are all diseases which result in significant economic loss
for cattle and dairy operations in Tennessee. Leukocytes
(white blood cells) are an important part of the immune
system and contribute to defense against many of the in
fectious agents which cause these diseases. Yet the rea
sons for occasional breakdown in the defense systems
often are unknown. The main focus of Dr. Bochsler's labo
ratory is the basic mechanisms by which leukocytes can
prOVide protection aga inst infectious agents that affect
cattle. The research concentrates on the actions, interac
tions, and synthesis of immunologically active products of
white blood cells and cells lining blood vessels. Of par
ticular interest is the responses of these cells to a compo
nent (endotoxin) of certain bacteria (Gram negative), that
commonly cause serious bovine diseases. Better under
standing of bovine white blood cells and the immune system will
help uncover the essential events in disease production by infec
tious agents. This information should eventually frame the basis for
improved strategies of prevention and therapy.
When liberated from gram-negative bacteria in sufficient
quantity, bacterial endotoxin elicits symptoms and adverse effects
that may progress to multiple organ failure and death. Endotoxin
binds to various substances in the blood, and on certain cells, is
part of its action and metabolism. Dr. Bochsler determined that,
unlike humans, the receptor to which endotoxin binds is present on
the surface of bovine blood vessels. This suggests that these cells
have a very high sensitivity and low activation threshold to this
bacterial toxin. It explains also some aspects of important vascular
and white blood cell responses to endotoxin in several diseases of
cattle. He also was able to isolate and analyze the gene encod
ing the surface structure (receptor) of the vascular lining cells to
which endotoxin binds .
Dr. Bochsler has investigated the factors affecting nitric ox
ide production in lungs of cattle. Nitric oxide (NO) is a short-lived

12

Dr. Philip N. Bochsler.

chemical reactant produced by many cells of the
Bac:teria 
body, and has an important role in host defense
against certain microbes , such as bacteria. He
showed that nitric oxide is produced by lung scav
@yLBP
enger cells (alveolar macrophages) , but the ques
<1'§)- LBP
Immu no'log1c
tion of whether sufficient quantities of this substance
Other
and
is produced for bacterial killing remains unan
r<J1icrobial
..
L6P InOammatory
swered. It was determined also that common res
AflllgenS? ~
. '. '. , ~ ...·R. esponses
~?~ .
piratory tract viruses of cattle (herpes and parain
fluenza) impairs production of nitric oxide by al
veolar macrophages.
t Gef1~
Another approach taken by Dr. Bochsler and
t Products
his group was to determine the relationship be
t "
tween bovine respiratory virus infection and fibrin
formation in the lung . Fibrin formation in the lung
is important because it is a common complicating
Mechanism by which bac
terial products (LPS) at
factor in bovine pneumonia and may interfere with successful
tach to scavenger cells
resolution of the disease.
(macrophage) causing the
release of biologically-ac
They found that inoculation of lung scavenger cells with
tive products.
a variety of bovine respiratory viruses increased production of
a substance (tissue factor) that is an initiator of fibrin formation.
A bacterial component (endotoxin) often enhanced production
of this substance by virus-treated scavenger cells . This work
has advanced our knowledge of the mechanisms involved in
the development of bovine respiratory tract disease.
Dr. Bochsler's research has been supported by the Cen
ter of Excellence and USDA.
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VIRUS MOLECULAR
BIOLOGY LABORATORY
Dr. David A. Brian
Fellows and Graduate Students : Dr. Savithra Senanayake,
Dr. Jennifer Black, Gwyn David Williams, Catherine Cardullo

Dr. Brian's interest in basic molecu
lar biology has resulted in discoveries of
fundamental biological mechanisms of vi
rus and cell replication for which he has
received national and international recog
nition. His research exploits basic viral and
cell biology discoveries for the control and
therapy of important viral diseases of ani
mals and people.
Coronaviruses cause some of the
most costly respiratory and gastro-enteric
diseases among livestock and fowl and dis
abling diseases of people. Efforts to control coronavirus infections
have been frustrated by three major obstacles:

1.
2.

3.

A weak immune responses in animals to coronavirus
vacci nation.
A logistical problem of inducing protective mucosal
immunity in the newborn (often the most vulnerable
victim of coronavirus infection).
An ability of coronaviruses to rapidly mutate into
new pathogenic variants .

The pri ma ry resea rch focus in Dr.
Brian's laboratory is the molecular biology of
coronavirus replication with the goal of de
termining how this virus induces disease. They
have discovered a fragment of the virus gene
(subviral replicon) of the bovine coronavirus
that replicates in the presence of Wild-type
virus. This minigenome is being engineered
experimentally to carry many kinds of poten
tial antiviral molecules into cells . One mol
ecule is an enzyme (ribozyme) designed to

14

Dr. David A. Brian.

Dr. Brian and staff.
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Figure 1: Electron micro
scope of bovine coronavirus
replicating in human prostate
cells. This is the first evidence
of susceptibility of human
prostate cells to coronavirus
infection. Corona-viruses are
identified by arrowheads.
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Figure 2: Replication scheme
for coronaviruses. Adapted
from K. Holmes and M. Lai,
Virology, 1996.
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destroy the
on which the virus depends for repli
cation (polymerase gene).
novel therapeutic ap
proach could cure a virus-infected
. Another mol
ecule is a gene for
protein (antigen) that might
stimulate superior immunity against the coronavirus
when inoculated into animals .
With funding from the USDA and the
and
modest support from the Center of Excellence, they
are making an intense
systematic effort to under
stand how five separate genetic structural elements in
the coronavirus gene (genome) fundion to regulate
production of viral proteins. This information will have
a significant impact in designing additional control
therapeulic strategies for
coronaviruses.
Through the study of the
nigenome, Dr. Brian recently
discovered regions at ,the ends of the virus genetic material that
(promoter regions
are potential sites for targeted antiviral
for the virus' replicating enzymes).
Of great interest is how a newly discovered segment in
virus gene regulates replication
the genome.
structure
is absolutely required in its entirety for genome replicaj'ion (RNA
pseudoknot a tRNA-like structure - in the 3' end of
bovine
coronavirus genome). The hypothesis is that the RNA pseudoknot
regulates produdion of viral
which first must be accom
plished before viral genetic material can be
. By un
derstanding how this structure regulates this function, it may be
struc
possible to develop a therapeutic antiviral molecule.
ture-function relationship described for
pseudoknot is novel;
its function in this role (as
a transfer RNA-like
ment) apparently has not
described
any
animal virus. An
additional hypothesis is
that the tRNA-li
pseudoknot bi nds to a
common cellular protein
component of protein
produdion machinery
(his'l'idyl tRNA syn
thetase).
use the
latter is involved in poly
(as an antigen),
an autoimmune
in humans, a connection
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between coronavirus infection and autoimmune disease may exist. If so,
this would also
a novel fi
ng and may uncover a means by which
particular disease could
controlled.

.....
...
....
....
...
.....
....
..

.

.....
..
.,
....
...
.....,
....
..•
...,
...
...
...
..
.,

.,
.,

...
...

...
...

16

.....

TUMOR BIOLOGY
LABORATORY
Dr. Kevin A. Hahn
Staffand Graduate Students: Dr. Ahmed Shoieb, MaryAnne Barnhill,
Tracy Diehl, Marie Nolan and Jason Yarbrough

Dr. Kevin Hahn.

Many tumors and cancers can be treated effectively w ith
certain drugs. Unfortunately, resistance to several drugs is becom
ing a serious problem in cancer therapy. Dr. Hahn 's working hy
pothesis is that modification of the activity or function of a certain
enzyme (glutathione-S-transferases) will result in the reversal of anti
cancer drug resistance and improve patients' response to therapy.
Dr. Hahn 's approach to confirming this hypothesis is to exploit a
specific inhibitor of this enzyme and to determine whether it can
reverse drug resistance in different systems.
Earlier work by Dr. Hahn established
that the enzyme (glutathione-S-transferases)
is responsible for resistance to the d rug
cisplatin and that the inhibitor (ethacrynic
acid) reversed this resistance in cancer cells
grown in the la boratory. Dr. Ha hn cu rrently
is evaluating whether the inhibitor can re
verse the drug resistance in an animal. He
is using an animal model consisting of the
nude mouse, implanted with drug resistant
tumor cells or with drug sensitive tumor cells
for comparison purposes. Dr. Hahn has
shown also that the blood concentration of the enzyme (glutathione
S-transferases) is correlated with the successful treatment with an
other drug (doxorubicin) of dogs with lymphoma. Therefore , moni
toring blood concentrations of this enzyme regularly during treat
ment may allow clinicians to identify drug-resistant patients early
and initiate alternative treatments. This would decrease the likeli
hood of subsequent remissions and extend patients ' life span .
In another approach to improve cancer therapy, Dr. Hahn
is using a dog model in an detect the recurrence of lymphoma
before it is clinically apparent. In this study they measured the
concentration of a substance (ACid Glycoprotein) in blood in sev
eral dogs during clinical remission after haVing had lymphoma and
treatment with doxorubicin . They found that blood concentration of

17

Acid Glycoprotein increased significantly just prior to the onset of a re
lapse. Therefore , an elevated level of this substance is useful in predicting
lymphoma progression in patients after treatment. This also should be very
useful in the management of drug-resistant tumors .
This research is funded by the Center of Excellence , Morris Animal
Foundation a nd the Bayer Corporation.
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TALL FESCUE
TOXICITY LABORATORY
Dr. Jack W. Oliver
Staff: Dr. Eric Schultze, Dr. Robert Linnabarry, Kim Abney,
Elizabeth M. Bailey and Jane Czarra

Dr. Jack W. Oliver.

Tall fescue is the predominant cool-season grass grown in
Tennessee and much of the Southeastern United States, and is
common forage for cattle and other grass-eating species (herbi
vores). Most of the tall fescue grown in the U.S. is infected with a
fungus (Neotyphodium coenophialum) that produces po
tent chemical agents known as ergot alkaloids. These
alkaloids are harmful to livestock and result in serious eco
nomic losses to producers. The tall fescue toxicosis syn
drome in herbivores is widely recognized as the primary
grass-induced toxicity for animals in the U.S. There are
more than 3.5 million acres of tall fescue in Tennessee ,
approximately 10% of the total U.S. acreage . Annual
animal production losses to the state due to livestock con
suming the infected forage are estimated at 100 million
dollars . Production losses occur because of severely im
paired weight gain, milk production and reproduction in
animals that consume contaminated grass.
The ill effects caused by ergot alkaloids ("ergotism")
is certainly not a new disease entity, having been recog
nized in people for hundreds of years. The disease in
humans is associated with the eating of grains contami
nated with a fungus (Claviceps spp.-" ergotized") that produces
alkaloids similar to those present in infected fescue grass . Tissue
lesions in people caused by ergotized grains were described in
the 1930s, and outbreaks of a similar disease in cattle identified
in the 1950s was associated with grazing on Kentucky 31 tall
fescue grass . The incrimination of fungus contamination of tall
fescue grass as the cause of toxicity in cattle was made by a
group of researchers at the University of Georgia in 1977. How
ever, despite numerous studies at Southeastern Land Grant Col
leges designed to understand and alleviate the disease problem
and intensive discourse among researchers worldWide, produc
tion losses continue in animals that graze contaminated tall fescue
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grass.
The long-term goal of tall
fescue research is to prevent the
health problems in herbivores that
consume the grass, while main
taining the drought and insect re
sistance imparted to the plant by
the presence of the fungus and
the ergot alkaloids. Development
of an effective vaccine or chemi
cal treatment is needed to counter
100 360 500
the toxic effects in animals, that
SCA LE OF MILES
would allowing full usage of this
valuable forage . Alternatively,
Figure showing tall fes
cue use/adaptation .
identifying the specific toxic alkaloids in tall fescue grass will allow
From R. Buckn er & L.
plant scientists to genetically manipulate fescue grass to eliminate
Bush (Eds.), Tall Fescue
(1979), p.15.
toxic alkaloid production.
Research by Dr. Oliver and his co-workers on reducing the
severity of the disease has, among other advances, resulted in de
velopment of an effective anti-fescue toxicosis vaccine (U .S. patent
awarded). The nutrient content of tall fescue is excellent and this
forage could be exploited even more widely if the associated health
problems in herbivores could be prevented . The grass is well es
tablished, and valued for its vigor and root establishment making it
an important factor in control of soil erosion, and an extremely
popular turfgrass.
The short-term goals of fescue toxicosis projects have fo
cused on injury to cardiovascular tissues of animals consuming fun
gal-infected tall fescue grass. Although much remains to be learned,
excellent progress has been made. Dr. Oliver's work has estab
lished that vascular damage may be the central event induced by
ergot alkaloids in animals:

1.

2.

3.

4.
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The ability of blood vessels to contract is increased
by changes in blood vessel structure (alpha-adren
ergic-2 receptors) that trigger vessel narrowing.
Soluble chemical factors released by the cells that
line blood vessels further produce vessel contraction
and narrowing (thromboxane A2, angiotensin II).
Circulating ergot alkaloids from fungal-infected fes
cue result in the release of factors that promote blood
clotting (Von Willibrand factor) and damages lining
cells of blood vessels.
Damage to the lining cells of blood vessels and the

associated attempt at repair (platelet aggregation and blood
clotting), result in release of factors that cause vessel wall
thickening (serotonin, thromboxane A2, angiotensin II).
As a consequence of injury to blood vessels, blood
flow to tissues is impaired thereby affecting the function of
body systems . Examples include:

1.

2.

3.
4.
5.
Dr. Oliver and staff.

Decreased blood flow to the skin affects haircoat
quality (unthrifty appearance) and contributes to
heat stress in animals by interfering with heat loss
from body surface.
Altered blood flow and blood clotting in the small
vessels of lung tissues impairs oxygen distribution to
tissues, and decreases heat loss via the lungs.
Altered blood flow to mammary tissues contributes
to decreased milk production.
Altered blood flow to reproductive structures affects
reproductive capacity.
Decreased blood flow to the intestines and the
liver affect body metabolism and suppresses
growth (decreased weight gains).

The achievements of the researchers in the College
was recognized in 1997 by an invitation to Dr. Oliver to
deliver a plenary paper on the physiological manifesta
tions of fescue toxicosis in ruminants at the Third Interna
tional Symposium on Fescue Toxicity that was held in Ath
ens, Georgia, May 28-31, 1997. Over 100 research
ers from 14 countries attended this major, worldwide event.
In October of 1997, USDA awarded a substantial com
petitive research grant to Dr. Oliver and co-workers for
three years to continue study of mechanisms of toxicity
caused by the fescue alkaloids. The study will allow con
tinued in-depth examination of toxic mechanisms of alka
loids, and will establish relative toxic effects of the major
alkaloids found in fungus-infected tall fescue.
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MASTITIS RESEARCH
LABORATORY
Dr. Stephen P. Oliver
Post-doctoral Research Associates and Staff: Dr. Raul Almeida, Dr.
Weihuan Fang, Barbara Gillespie, Mark Lewis, Doug Luther, Susan
Ivey, Lori Coleman

Research conducted by Dr. Oliver focuses on mastitis in
dairy cows caused by environmental organisms . Obiectives are
to :

1.
2.

3.

Characterize factors that affect resistance of the
udder to mastitis.
Characterize factors and mechan isms, that per
mit mastitis pathogens to invade the udder and pro
duce mastitis .
Develop and evaluate techniques for the preven
tion and control of mastitis in dairy cows.

Dr. Oliver's resea rch program incor
porates both applied and basic research.
Applied studies concentrate on issues of con
cern to the dairy industry that can have an
immediate beneficial impact. This research
includes strategies for controlling mastitis in
heifers and the influence of mastitis on re
production of high-producing dairy cows.
Basic research is aimed at discov
ering innovative methods of mastitis control
by exploiting biotechnological advances .
This research includes development of
nucleic acid probes for rapid and accurate detection of mastitis
organisms and organisms responsible for food poisoning. Other
studies being done concern virulence (severity) factors produced
by and immunity to certain mastitis-producing organisms (strepto
coccus species) in cows . They also are attempting to identify dis
ease-resistant genes of dairy cattle.
Mastitis is caused by several kinds of bacteria that are ca
pable of infecting the udder. Mastitis pathogens invade the udder,
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Dr. Stephen P.
Oliver (center)
and staff.
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mulliply there and produce harmful substances
that result in inflamma"l"ion, reduced milk produc
lion and altered milk quality. Control of mastitis
is extremely difficult because of the many types
and sources of mastitis pathogens that can cause
the disease. The National Mastitis Council esti
mates that mastitis costs U.S. dairy producers
over two billion dollars annually. In Tennessee,
losses due to mastitis may exceed $25 million
annually. Thus, mastitis in dairy cows is likely
the most costly disease affecting dairy produc
ers in Tennessee, the U.S., and throughout the

.,
.,
.,

Figure 1: Electron micro
scope view of bacteria at
tached to a milk-secreting
cell.

.,

.,

world.
Dr. Oliver has increased the awareness of scientists,
extension specialists, dairy producers, pharmaceutical companies
and other members of the dairy community of the importance of
environmental pathogens in bovine mastitis. Furthermore, he has
discovered fundamentally-important information that is critical for
controlling the heterogeneous organisms that cause mastitis. The
ultimate goal of Dr. Oliver's research is to enhance the quantity
and quality of milk produced by and to reduce the economic
impact of mastitis for dairy producers in Tennessee, the U.S., and
throughout the world. One aspect of this work is to develop a
vaccine to prevent mastitis and thereby eliminate the need for
treatment with antibiotics.
Dr. Oliver was the first to show that mastitis in pregnant
dairy heifers occurred frequently near calving and that many of
these infections persisted into early lactation. His research has
resulted in a simple, effective and inexpensive method for control
ling mastitis in heifers. Intra-mammary antibiotic infusion before
calving, was shown to be an effective procedure for:

1.

2.

.,
3.

-

Eliminating many infections in heifers during late
gestation.
Reducing the prevalence of mastitis in heifers dur
ing early lactation .
Reducing the prevalence of mastitis in heifers
th roug hout lactation.

Several studies over the past 1 3 years at the UT Dairy
Experiment Station involved collection of milk samples for micro
biological evaluation at intervals before calving, during lactation
and during the dry period. About 15,000 samples are collected
and processed each year from cows in this herd. Data hom those
studies have been computerized, producing perhaps the largest
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...
mastitis database in the world. It now is being
exploited for retrospective studies and will pro
mas
vide valuable informaj'ion on the spread
titis pathogens
as Streptococcus uberis
and Streptococcus dysgalactiae, in
h-pro
ducing dairy herds.
Recently they evaluated the influence of
mastitis on reproduction in Jersey cows and
found it profoundly impairs reproduction dur
ing early lactation. Consequently, two propos
by the American Jersey Cattle Associal"ion
als were funded
by which mastitis can influence reproduc
delineate mechan
performance.
Dr. Oliver has been aCl"ively
the identification of
virulence (severity) factors produced by certain mastitis organisms
(streptococcus
and implical"ions of immunity to them. In
ma ny do i ry
Streptococcus
a nd Streptococcus
h proportion of mastitis with
dysgalactiae are responsible for a
varying degrees
severity in lactating and non-lactating dairy
cows. Strateg
for controlling these masl'itis pathogens are poorly
defined and inadequate. This research focuses on:
l

1.
2.

characterization of

uberis and

Characterization of S.
and S. dysgalactiae
with particular emphasis on factors involved in ad
and invasion into mammary epithelial
Is.
Evalual"ion of immunity
immunization of dairy
cows with components
uberis and S.
Y"lCJr,CJn,'r.

3.

Figure 2: Electron micro
scope view of a section
through a milk-secreting
cell containing several bac
teria.

...
...
...

.
...
...

...

alactiae.
4.

rTlL~r·I".J=rl'=CC of experimental vaccines to S.

dysgalactiae mastitis during the nonlactating
Dr. Oliver's research group determined that S. uberis and
dysgalactiae readily adhered to and invaded cells lining
bo
res 1 and 2). Chronic infections then may
vine udder
develoPI and
intracellular
protect these
from anti-microbial drugs and host
mechanisms. Mastitis
pathogens
in the presence of mammary epithelial (lining)
cells in the laboratory synthesize proteins not detected when
ria are cultured alone. These unique proteins likely are involved in
virulence of bacteria including their capacity to adhere and invade
Thus,
of
pathogens in
mammary epithelial
laboratory in the
of mammary epithelial cells may
r'\/"'iI"TCJril/"'i
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Dr. Oliver and staff.

in expression of bacterial virulence factors similar to that which
occurs in the animal . This important discovery will be exploited for
the development of vaccines and management of mastitis.
Dr. Oliver has communicated results of his research via
scientific and popular press publications, and via presentations to
several different target groups at state, regional, national and in
ternational meetings and conferences. There is considerable inter
est in this work throughout the dairy community, and Dr. Oliver has
been a popular speaker and author on heifer mastitis and its con
trol. In addition, Dr. Oliver has made several
presentations to groups such as The Univer
sity of Tennessee Agricultural Committee
Board of Trustees, the Institute of Agriculture
Development Board and the 21 st Century
Campaign Steering Committee, Tennessee
Agricultural Experiment Station Department
Heads' Conference, and the Tennessee
Higher Education Commission Center of Ex
cellence Review team. This spring, Dr. Oliver
has given presentations entitled "The Univer
sity of Tennessee Mastitis Research Program : Making a Difference
Through Research" to the Tennessee House of Representatives Ag
riculture Committee, to The University of Tennessee Institute of Ag
riculture Alumni Council, and to The University of Tennessee Insti
tute of Agriculture Development Board and Agriculture Steering
Committee for the 21 st Century Campaign.
Dr. Oliver's research in mastitis was recognized by the
UT Institute of Agriculture in 1998 with the Pendergrass Award.
The award, named for former vice president for agriculture
Webster Pendergrass, is presented in tribute to a faculty member
who has contributed most to the fulfillment of the Institute's goals .
Dr. Oliver's research has been supported for several years
by the Center of Excellence, but his primary funding has been
derived from substantial grants from foundations and the pharma
ceutical industry.
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VIRAL IMMUNOLOGY
LABORATORY
Dr. Barry T. Rouse
Fellows, Staff and Graduate Students: Uday Kumaraguru, Teresa
Sobhani, Dr. Johnson Thomas, Dr. I/a Davis, Massoud Daheshia,
Dr. Shivaprakash Gangappa, Sirdhar Govindaswamy Dr. Nelly Kuklin,
Shilpa Deshpande, Dr. Stewart Novinger, Dr. Zhiya Yu, and Sangjun
Chun

Dr.

Rouse's research deals with the issue of how the body

recognizes and interacts with viral infections. The virus they study is
herpes simplex virus, an agent that affects up to 80% of mankind.
This virus causes a variety of diseases, but is rarely lethal. Follow
ing initial infection, the body usually fails to cast out the virus, and
it persists in association with cells of the nervous system in a condi
tion called latency. Unfortunately this state of affairs is not perma
nent, since periodically some latently-infected
nerve cells reverse their interaction, and new
virus is produced which may cause a second
ary expression of lesions. Such recrudescent
lesions occur frequently in some individuals and
are the cause of considerable pain and dis
tress. Much remains unresolved regarding the
nature of the interaction of the herpes simplex
virus with its host. One such unresolved issue
is why the reactivation episodes are clinically
significant in some individuals, but unnoticed
in others. A likely answer to this question lies in the effectiveness of
one or more components of the immune defense system. However,
this is a difficult issue to study in the human host.
The Center of Excellence supports some aspects of this re
search, but it is funded primarily by very substantial grants from the
National Institutes of Health. Their research has generated na
tional and international interest, and the laboratory is recognized
as one of the premier viral immunology programs in the country.

Value of Animal Models
Dr. Rouse's approach to understanding the interaction be
tween HSV and the immune system has been to use model infec
tions in experimental animals, using the mouse and a variety of
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Dr. Barry T. Rouse.

routes of infection. Thei r aim is to identify
immune defenses that best correlate with pro
tection, seeking a means of vaccination and
immune manipulation to enhance the effi
ciency of appropriate immune defenses.

Immunity to Herpesvirus Infections

1) Normal cornea (top photo)
2) Diseased cornea (bottom
photo).

Currently, Dr. Rouse's major approach is
to use novel vaccines composed of nucleic
acids, which encode selected proteins of HSV
as a way of inducing protection. They com
bine this approach with the co-administration
of molecules that can manipulate the quality
of immune responses induced. Thus, it is
known that molecules (so-called cytokines) re
leased by the body's own T lymphocytes and
other white blood cells may profoundly influ
ence crucial events of the immune response.
Accordingly they have found that the pres
ence of some of these cytokines results in
prompt and effective immune induction
whereas the presence of others may lead to
a type of immunity that is less effective. They
are exploring the use of DNA, encoding various cytokines,
given at different intervals in relation to either infection or immu
nization for their effect on the level of immune protection. Their
results may provide clues useful for the design of future herpes
virus vaccines.

Disease Caused by Immune Responses to
Herpesviruses
The immune response to a virus is not always a benefi
cial protective event. In some situations aspects of immunity
seem to account for development of lesions. Such situations are
usually referred to as immune pathologies. At least one dis
ease process caused by herpes simplex virus infection may
represent an immunopathological event, the Herpetic Stromal
Keratitis (HSK) syndrome. HSK involves the cornea of the eye
and is the most common infectious cause of vision impairment
in the USA. Many thousands of persons are affected, and a
significant number require corneal transplants. Dr. Rouse is
attempting to understand the various events that result in kerati
tis with the ultimate objective of finding steps amenable to ma
nipulation for minimizing lesions. They have identified many of
the host cells and their products involved in lesion development
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in mice . They showed also that, if the ani
mals are genetically unable to generate im
mune responses or if certain aspects of im
munity are suppressed, keratitis does not de
velop. This is the primary evidence sup
porting the notion that herpes keratitis is, in
fact, an immunopathological lesion, i.e.
without a response by the immune system,
damage to the eye would not result.
It would not be wise to totally sup
press immunity in an attempt to control HSV
because, without some immune protection, the virus may spread
beyond local sites (such as the eye) and cause damage to the
nervous system. This may have lethal consequences. There may
be more subtle ways of adjusting the immune response such that
protection will be preserved and pathology diminished. One way,
discovered in Dr. Rouse's laboratory, that seems to accomplish this
objective is to adjust the cytokine environment of the cornea using
DNA vaccines encoding cytokines. One cytokine, called IL-10,
appears particularly useful for this purpose.
Although replication by the virus in the eye appears as an
essential event to set off keratitis, they found that the continued
presence of the virus is not needed for persistence of the inflamma
tory process. Indeed it could be that the virus somehow sets off an
inflammatory event that, in its latter stages, becomes an autoim
mune reaction.
According to this idea, herpes simplex virus may damage
the cornea, causing a slight change in tissue composition such that
it then becomes the target of the immune response. Some research
results even suggest that a component of the virus itself may act as
a molecular mimic of the host protein that then drives autoimmunity.
Dr. Rouse and his co-workers are striving to evaluate these ideas on
the role of the immune response in herpes keratitis using a variety of
genetically-defined animal model systems. They hope that their re
search will culminate in an understanding of the molecular and cell
specific steps that occur during keratitis, and that clues will emerge
as to how best to manage this tragic disease in people.

28

Dr. Rouse and staff.

EXPERIMENTAL ONCOLOGY
LABORATORY
Dr. Hildegard M. Schuller
Fellows, Staff and Graduate Students: Dr. Howard K. Plummer
III, Dr. Diann L. Weddle, Dr. Barbara J. Sheppard, Dr. Brian A.
Jull, Michelle R. Williams, and C. Brian Porter

Dr. Hildegard M.
Schuller.

Lung cancer is the leading cause of cancer deaths in all
industrialized countries . East Tennessee has one of the highest
lung cancer rates in the nation. Although cancers at other or
gan sites are more than twice as common , their cure rate is
considerably higher. The most common cancer in men is pros
tate cancer with a cure rate of 84% . Breast cancer is the lead
ing type of cancer in women with a cure rate of 74%. By
contrast, 158 ,700 (89 .3%) of the 177,700 patients diagnosed
with lung cancer in the year 1997 died within 1 2 months of
diagnosis .
Smoking and exposure to second hand smoke are the
most intensively studied and best-documented risk factors for
the development of lung cancer. Contrary to cancers at other
organ sites , the incidence of lung cancer continues to rise in all
industrialized nations. Moreover, teen smoking in the U .S. has
increased at an alarming rate, thus setting the stage for even
higher numbers of lung cancer cases 30-40 years from now.
Another important contributing factor to the rise in lung cancer
cases is the growing number of lung cancers developing in
individuals who have never been exposed to primary or sec
ond hand smoke. This trend, which has been globally ob
served during the last two decades in all industrialized coun
tries, is particularly evident for pulmonary adenocarcinoma. Of
the six types of lung cancer recognized by the World Health
Organization (WHO) classification, two (small cell carcinoma
and adenocarcinoma) account for 90% of all lung cancers,
with 30% of these cases unrelated to a history of exposure to
primary or second hand smoke.
The lung cancer "epidem ic" is closely related to an in
crease in chronic lung diseases such as bronchitis, bronchioli
tis, asthma, emphysema , and chronic obstructive pulmonary
disease. For all lung cancer types, chronic lung disease has
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been identified as a risk factor even
without a history of exposu re to
smoke. This disease complex,
which often is referred to as "aller
gies," has the same geographic
distribution as lung cancer with
which it shares some risk factors
such as smoking and air pollution .
It has been stated that East Tennes
see is "the land of allergies."
Dr. Schuller's research has
been dedicated to the study of lung
cancer for over 20 years. It is her
belief that effective strategies for the prevention and therapy of this
disease complex can only be based on an in-depth understanding
of the regulatory mechanisms which govern the growth of normal
lung cells and the cancers arising from such cells. Contrary to
other researchers who are searching for the "magic molecular event"
responsible for the genesis of all lung cancers, she hypothesized
that different lung cell types and different types of lung cancer may
be governed by different regulatory mechanisms. These in turn
may be differently affected by known risk factors for the disease.
Dr. Schuller's achievements in lung cancer research have
been recognized nationally and internationally. Her research has
been supported by the Center of Excellence, but her primary sup
port comes from substantial grants of the National Cancer Institute
and the pharmaceutical industry.

Recent Achievements
Dr. Schuller's recent research has been prompted by the
epidemiological evidence which links small cell lung carcinoma to
both smoking and chronic lung disease. Her group is exploring
whether factors exist unique to tobacco constituents and chronic
lung disease that might interfere with growth regulation in these
types of cancer cells and the normal cells from which they originate
(pulmonary neuroendocrine cells). Using this approach, they found
that the growth of these normal cells is regulated by an aspect of
the nervous system (autonomic) via the release of a chemical mes
senger from nerve endings (the neurotransmitter acetylcholine). They
have identified the molecular mechanism that triggers specific growth
of this cell type. The first discovery was that the chemical messen
ger binds to a specific surface structure unique to these cells.
They now have dissected the chemical events that are trig
gered by the binding of the chemical messenger to the receptor. It
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Lung tumor induced in a
hamster by a metabolic
product of nicotine and
increased intrapulmo
nary carbon dioxide.

Dr. Schuller and staff.

culminates in the release of a growth fac
tor, serotonin, into the blood stream . The
release of this growth factor selectively stimu
lates the growth of the neurendocrine cells .
Their studies showed that nicotine and its
prod uct prod uced in the body sti mulate the
production of high levels of this growth fac
tor by binding to the receptor on these cells.
Minute amounts of these tobacco-specific
agents therefore act as powerful and selec
tive growth stimulators for these cells in smok
ers . Their experiments also showed that carbon dioxide selectively
sensitizes the receptor to nicotine, thus dramatically promoting the
release of the growth factor and growth stimulation in response to
these tobacco-specific toxicants.
Chronic lung diseases impair pulmonary ventilation, thus
increasing the concentration of carbon dioxide in the lungs . The
increased carbon dioxide therefore drastically increases the likeli
hood for the development of small cell lung cancer in smokers . In a
hamster model developed by Dr. Schuller, this hypothesis gains
powerful support from their finding that nicotine and its metabolic
product, which is non-carcinogenic in healthy animals, causes lung
tumors in hamsters under conditions of increased intrapulmonary
carbon dioxide.
Their findings explain why small cell lung cancer is virtually
never found in nonsmokers and why among those who smoke, this
cancer type develops primarily in individuals with chronic lung
disease. Moreover, these data prOVide a basis for the develop
ment of novel drugs and treatments for this lung cancer type .
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BIOLOGICAL ACTIVITY
TESTING AND MODELING
LABORATORY
Dr. Terry W. Schultz
Staff and Graduate Students: Glendon Sinks, Betsy Gregory and
Anna Bearden

Modern society uses and misuses hundreds of thousands
of organic chemicals. While the need for information to aid indus
try and government in hazard and risk assessment of chemicals
has never been greater, only limited toxicological assess
ment has been done on a small fraction of these chemi
cals. At the same time the resources allocated to generate
these data are being reduced. As a consequence, the
field of structure-toxicity has been developed and is pro
viding important answers in a timely and resource-efficient
manner. Today, structure-toxicity models are considered re
liable tools for use in hazard and risk assessment. Dr.
Terry W. Schultz, at the University of Tennessee's College
of Veterinary Medicine has been a leader in the develop
ment of this science.
Structure-toxicity relationships correlate toxic potency
of chemicals to their chemical properties. Since proper
ties of chemicals are related to their structure,
structure
..
toxicity studies investigate the sort of chemical structure that will
produce a well-defined adverse or toxic response. Structure-toxic
ity studies have been conducted for over a century. A. F. A. Cros
defended his thesis entitled: "Action de I'alcool amylique sur
I' 0 rg ani s me" befor e the Fa cui ty 0 f Med i ci ne , U n i ve rsi ty 0 f
Strasbourg, Strasbourg, France on January 9, 1863. He noted
the relationship between the toxicity of simple alcohols and their
water solubility. This relationship demonstrated the central axiom
of structure-toxicity modeling - the toxicity of molecules is reflected
in their chemical structure. The science of structure-toxicity is truly
an integrated one (see figure, opposite page).
The objective of structure-toxicity analyses is to define, as
accurately as possible, the limits of variation in the structure of a
chemical that are consistent with the production of a specific toxic
effect. Moreover, such analyses examine ways in which alter
ations in structure and overall properties of the molecule influence
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Quantifiable toxicology
involves numerous dis
ciplines.

toxicity. If enough data related to toxicity become available, a
hypothesis can be developed regarding the molecular basis of in
teraction between the toxicant and the site of its toxic action in the
body or cell .
Dr. Schultz directs the Biological Activity Testing and Model
ing Laboratory in the College of Veterinary Medicine at the Univer
sity of Tennessee , which has had a long-standing interest in struc
ture-toxicity modeling . The U.S. Department of En
ergy and the U .S. Environmental Protection agency
are the primary sources of funding for this research.
The Center of Excellence also has invested in this
research, which during the past 15 years it has pro
vided expertise to industry and agencies not only in
Tennessee, but also to the entire nation . Moreover,
Dr. Schultz has built a solid international reputation
in the field through collaborative efforts throughout
the world.
Since the establishment of the Center of Excellence in live
stock Disease and Human Health in 1985, the Biological Activity
Testing, and Modeling Laboratory has tested an average of more
than 100 chemicals per year. This work has developed the largest
chemical toxicity database in the world . The long-term goal of this
program is to develop a computer-aided , knowledge-based system
that will predict acute toxic potency from molecular structure. The
current version accurately models the toxicity to humans of about
75% of the industrial organic chemicals .
The short-term goal of this program is to develop a better
understanding of man-made chemicals that cause disruption of en
docrine (hormonal) systems. In particular, their current project fo
cuses on identifying the molecular structural features associated with
industrial organic chemicals that mimic estrogens . Recent achieve
ments by this group include the prediction of the capacity for chemi
cals to form highly toxic , free radicals (reactive products) by certain
biochemical mechanisms (either by photo-induction or by mimick
ing synthetic cytochromes).
As we enter the 21 st century, the Biological Activity Testing
and Modeling Laboratory stands ready to assist industry and gov
ernment to address toxicological problems by acquiring specific
data and to develop tools to be used in predicting toxicity from
molecular structure.
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ANTICANCER MOLECULAR
ONCOLOGY LABORATORY
Dr. Hwa-Chain R. Wang

Dr.

Wang's long-term research goals concern tumor-spe
cific intracellular molecular signaling network and to uncover sig
naling pathways that can be induced by anticancer agents, lead
ing cancer cells to a programmed cell death (apoptosis) .
Short-term goals are to identify intracellu
lar signaling elements whose activation is in
volved in induction of apoptosis of cancer cells.
A corollary to this is to identify novel anticancer
agents which may selectively induce apoptosis
of cancer cells, while sparing normal cells. Ulti
mately, he expects to apply the understanding
of intracellular signaling control to anticancer
therapeutics .
Currently, Dr. Wang focuses on two ap
proaches. The first is to understand the molecu
lar and cellular function of a novel intracellular
enzyme, which is activated in cells at the late stage of cellular
malignancy and in cells undergoing programmed cell death in
duced by forms of acute stress. The second is to study molecular
and biological activities of a novel natural anticancer agent, which
selectively induces programmed cell death of cancer cells .
Dr. Wang has identified a novel enzyme (kinase SAMK/
Krs 1) that is activated in cells at the late stages of transformation
into cancer cells . The same enzyme is also induced in cells under
going programmed cell death as a result of a variety of physiologi
cal, chemical or physical stresses. Dr. Wang
determined that the gene encoding this en
zyme might represent a member of a new
kinase enzyme family. He is investigating
the molecular and biological roles of this
enzyme gene in cancer development and
programmed cell death. Uncovering the ap
parent novel signaling pathway that cross
links cancer development of cells to pro
grammed cell death should be directly ex
ploitable for development of anticancer
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Dr. Wang and staff.

therapeutics .
Investigation into the mo
lecular mechanisms of potential
Physical, chemical, or biological st r
s ej
\
Mutations a£f~tjng metabolic
lea:iing to Programmed Cell Death
Intracellular Signaling Pathways
anticancer therapeutic agents
on a variety of cancer cell types,
Proarammed
Transformation into
particularly human breast can
Cell Death ..
Cancer Cello;;
CApQl?tosis )
cer
cells , is ongoing . Cancer
Research Goals:
Selective Induction of
ous mouse embryo cells and
Progranuned Cell Death
various human tumor cells are
in Cancer Cells
used to screen anticancer
Research goals.
agents. A novel natural substance was isolated from bacterial
cultures, and Dr. Wang discovered , it induces programmed
cell death in these cells whereas it merely inhibits growth in
normal cells . Studies on the molecular activities of this drug on
different intracellular metabolic signaling pathways suggest it
selectively induces programmed cell death in cancer cells only.
At least three important intracellular metabolic signaling path
ways are affected. Dr. Wang has made progress in testing this
phenomenon in cell cultures and is developing a unique model
for testing in an animal model (mice) . In the latter, he hopes to
determine the efficacy of this anticancer agent at different stages
of malignancy. His research therefore is unique in that it links
the molecular, cellular and animal system approaches in the
development of anticancer agents.
Dr. Wang's research is supported by the Center of Ex
cellence , but his primary funding source is the National Cancer
Institute .
Normal Cell Growth
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MOLECULAR GENETICS
LABORATORY
Dr. J. Erby Wilkinson
Fellows, Graduate Students and Staff: Dr. Carla Sommardahl,
Dr. Sharon Witonsky, Dr. Joanne Zahorsky, Nancy Nielson,
Marilyn Cottrell

Dr. Wilkinson's primary research focus is defining the role
of certain genes and gene products in specific diseases. Many
diseases of people and animals are the result of the cumu
lative effects of altered gene activity. Any given disease
may result from the increased or decreased activity of nor
mal genes, the activity of normal genes at the inappropri
ate time or place, or the activity of a mutant gene. Most
diseases are the result of the cumulative effects of all these
molecular events.
The group uses the tools of molecular and cellular
biology, informatics, the emerging technologies of genetic
manipulation of the mouse, and information generated in
the Human Genome Project to develop animal models of
human and domestic animal diseases. Unlike many other
groups, all their efforts start with the identification of a mu
tant mouse with a particular disease. They then use the
skills of clinicians, pathologists, and other researchers to
define the disease and identify the nature and effect of the muta- Dr. J. Erby Wilkinson.
tion.
r

They are actively involved in the development and identifi
cation of mutant animals, and have genetic 'tricks' to limit the num
ber of animals needed to produce mutations in every gene in a
specific region of chromosomes. By using "super mutagens," chemi
cals that produce many mutations in a cell, they are able to qUickly
produce and identify several mutations within a single gene. These
types of mutations are particularly important because they repre
sent a range of gene malfunctions that result in varying degrees of
disease severity. This information is especially useful to the pharma
ceutical industry, since any drug that is developed may only par
tially inhibit or enhance the function of a specific gene and its
metabolic pathway.
In addition to these newest mutations, known as saturation
mutants, the laboratory is also involved in the identification and
analysis of spontaneous mutants and various mutants produced by
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(top) Normal mouse.
(bottom) Mouse
with scurfy.

genetic manipulations. They use all the tools
of modern molecular biology and the tradi
tional tools of immunology, pathology, in
addition to developmental biology, to com
pletely evaluate the role of specific genes
in specific diseases . These studies, which
are part of the federal government-spon
sored human and mouse genome initiatives,
include collaborations with a number of in
vestigators at the Oak Ridge National Labo
ratory. Several projects have matured con
siderably in the past year, and several new
projects have been initiated.
They have identified a gene that causes a fatal congenital
kidney disease in humans (polycystic kidney disease). The various
forms of this disease represent a spectrum of diseases that are a sig
nificant health problem worldwide . One form is a significant cause of
mortality in newborns. In addition to closely mimicking human poly
cystic kidney disease, this mutant line of mice is unique in that the
mutant gene now has been cloned and characterized by Dr. Wilkinson's
group. Thus , for the first time, a gene directly associated with poly
cystic kidney disease was identified. Studies are underway to further
define normal structure and function of this gene to determine how
mutations in the gene result in the pathologic changes seen in the
disease, and to identify other genes affecting the severity of the dis
ease.
In addition, they have identified and characterized unusually
primitive cells in the livers and pancreas of these mutant mice. The
existence of such cells and the impact of their manipulation may be
important in the treatment of liver and pancreatic diseases. The re
searchers also demonstrated recently that the polycystic kidney dis
ease gene is an important factor in cancer of the liver, kidney, and
pancreas . From these studies, possible new avenues of therapy can
be explored.
Other projects include the analysis of a number of mutations
that alter the immune system . In one recently completed project, they
determined the cellular basis for a severe, rapidly fatal disease of the
immune system in certain (scurfy) mice. They are currently working
with collaborators to identify the mutant gene and determine how it
causes the disease . Another line of mutant mice has been analyzed
because of a high incidence of tumors. The tumors have been char
acterized and they anticipate cloning the mutant gene over the next
year. Their data indicates that a unique, uncharacterized gene re
sponsible for suppressing these tumors contains a mutation.
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INFORMATION DISSEMINATION
OF RESEARCH TO THE
GENERAL PUBLIC
Dr. Nancy Howell

Providing the public with information about Center of Ex
cellence research is an important activity of the College of Veteri
nary Medicine . To accomplish the goal of
disseminating research information, the col
lege utilizes many resources.
The college produces a general news
letter twice annually, distributed throughout Ten
nessee and beyond, which highlights research
activities. Features on on-going research, in
addition to results from concluded research
are included in the publication, Veterinary
News, which is written for general audiences.
Features appear in other University of Tennes
see publications, including UT Agriculture , UT
Alumnus and Tennessee AgriScience.
News releases are routinely distributed to state media, in
addition to certain regional and national media . Television and
print publications produce numerous features about the college
each year, many related directly to research conducted through
the Center of Excellence. Public displays about the college also
frequently include highlights of COE research . In addition, Center
of Excellence researchers are invited to share their research not
only professionally, but as speakers to commodity groups, civic
groups and other interested ind ividuals .
Another method of information dissemination is through the
college's site on the world wide web. Research is a major compo
nent of the site , with some COE projects , such as the tall fescue
toxicity research , including detailed information concerning their
progress .
Providing this material in the general media not only in
forms the public of important information, but helps the public bet
ter understand science and the practical applications of science to
their daily lives.
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Research information
is distributed through
a variety of UT publica
tions, as well as local
and national media.
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Table 3
RESEARCH PROJECTS FUNDED EXTERNALLY
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REPORT PERIOD 1996-97
PROJECT DIRECTOR

TITLE OF GRANT

FUNDING AGENCY

TOTAL AWARDED

ESTIMATED EXPENDITURES

David Bemis

Bordetella bronchiseptica adhesion molecules as
protective immogens and markers of host specificity

USDA 1433 Funds

$ 9,000.00
1% 1/96-9/30/97

$

Purification and characterization of bovine
lipopolysaccharide.binding protein

USDA

$184,000.00
8/31/97

$ 78,651.80

The role of nitric oxide as a mediator of host defense
cattle

USDA 1433 Funds

$ 6,852.00
10/01/95-9/30/96

$

6,852.00

Mechanisms of innate resistance to enteric pathogens of
bovine calves

USDA 1433 Funds

$ 8,322.00
10/01/96-930//97

$

3,548.50

Bovine coronavirus vector for mucosal immunity to
phaemolytica leukotoxin

USDA

$140,000.00
9/15/95·9/30/98

$

10,854.64

Mechanism(s) of coronavirus RNA replication and
packaging

National Institute of Allergies and Infectious
Diseases

$228,871.00
7/01/96·6/30/01

$

99,994.65

Thomas Doherty

Evaluation of gastric emptying in an endotoxin-induced
ileus model in the horse

USDA 1433 Funds

$ 5,000.00
10/01/96-9/30/97

$

1,195.00

Donita Frazier

Comparative cytochrome P450 drug metabolism
pathways of fish, poultry, and swine

USDA 1433 Funds

$ 4,000.00
10/01/96-9/30/97

James Godkin

Retinoids in bovine follicular and oocyte development

USDA Formula Funds

$

USDA NRI

Bachsler

David Brian

$

5,444.07

101.00

$

5,000.00

$212,000.00
9/01/93-8/31/97

$

34,913.34

AES Hatch

$ 15,000.00
7/01/96-6/30/97

$

3,748.37

5,000.00
0/01/95-9/30/96

K9TlnOla·Olnama protein and receptors in bovine

Maintenance of pregnancy in cattle and

Kevin Hahn

Serodiagnosis of Doxorubicin resistance in dogs

Morris Animal Foundation

$ 3,000.00
9/01/96-11/30/97

$

2,003.77

Melissa Kennedy

Detection f feline infectious peritonitis virus and
differentiation from feline enteric coronavirus

Morris Animal Foundation

$ 19,000.00
9/01/94-8/31/96

$

12,623.03

Characterization of 7A and 7B open reading frames of
feline coronaviruses

Pfizer Company

$ 8,750.00
7/01/96-7/31/97

$

8,699.75

Identification and expression of FIPV.specific peptides
and their use in FIPV-specific ELISA

Morris Animal Foundation

$ 23,725.00
1% 1/96-10/31/98

$
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$113,054.00
2/01/96-12/31/97

$

50,298.01

USDA 1433 Funds

$ 4,000.00
10/01/95-9/30/96

$

4,000.00

AES HATCH

$ 52,000.00
10/01//93-9/30/97

$

10,931.43

AES HATCH

$ 11,666.00
1% 1/96-9/30/97

$

1,666.00

Regulation of testosterone production in adult rat testis

Snow Brand Milk Products Co.
National Science Foundation

$ 30,000.00
$ 18,000.00
8/15/94-1/31/97

$

12,911.72

Increasing the sperm counts in testes of bulls using the
transient hypothyroid treatment

URCEO, France

$ 24,000.00
1/97-1/99
$ 47,320.00
5/01/96-7/01/97

$

39,320.22

Evaluation of fiber blends, enteric microflora, and diet
digestibility in cats with ileal cannulas

lams

Effect of volatile fatty acids on postweaning colonization
of Escherichia coli and Salmonella choleraesuis in pigs
Weaning and colonization of E. coli in the intestine of
young pigs

\...VlIliJUIlY

Characterization of mastitis causing agents in swine

Effect of galactosyl lactose on calf starter diets
Charmi Mendis-Handagama

Darryl Millis

The use of canine recombinant somatotropin to
enhance fracture healina in dogs

Monsanto Company

Pilot

G. D. Searle and

$ 50,749.00
9/19/96-6/30/97

$

39,652.84

Length of treatment time with canine recombinant
somatotropin for ostectomy healing in an unstable gap
fracture healing model

Protiva Company

$ 65,342.00
01/01/97-12/31/01

$

30,519.79

Initial dose determination of a new cylcoaxygenase-2
inhibitor for the prevention of lameness induced by
chemical synovitis in dogs

Protiva Company

$ 83,215.00
06/01/97-5/31/98

$

11,359.47

Protiva

$ 77,413.00
06/01/97-5/31/99

$

4,202.03

Contraceptive health surveillance center for zoo and
wildlife species.

Geraldine R. Dodge Foundation

$ 30,000.00
10/01/95-1/31/97

$

17,713.89

Continuing safety assessments of contraceptives for
non-domestic felids

American Association of Zoo Parks and
Aquarium

$128,414.00
1% 1/93-8/31 /97

$

50,829.84

Contraceptive health surveillance center for zoo,
wildlife, and companion animals

Geraldine R. Dodge Foundation

$ 25.000.00
01/01/97-12/31/97

Characterization of serum clinical chemistry analyte
profiles of cattle grazing endophyte-free and endophyte
infected tall fescue grass

USDA 1433 Funds

$ 10,000.00
1% 1/95-9/30/96

$

10,000.00

Anti-fescue toxicosis vaccine development

USDA 1433 Funds

$ 11,000.00
10/01/96-9/30/97

$

11,000.00

Anti-fescue toxicosis vaccine

Merck and Company

$ 60,000.00
1/01/95-12/31/96

of a new anti-inflammatory

for synovitis

Modulation of osteoarthritis with somatotropin and
polysulfated glycosaminoglycans in dogs using the

Linda Munson

Jack Oliver

~

W

Jack Oliver (continued)
~
~

Endothelin response to tall fescue stimulus of bovine
endothelial cells (Co-PI)

USDA

$ 60,002.00
3/01/95-8/31/96

Comparison of plasma cortisol concentrations after
stimulation with freshly reconstituted and previously
frozen and stored cosyntropin clinically normal dogs
(Co-PI)

American College of Veterinary Dermatology

$
2,250.00
7/01/96-6/30/97

American College of Veterinary Dermatology
$
3,000.00
4/01/97-3/31/98

The effect of exogenous oral melatonin administration
on sex hormone proladin and thyroid concentrations in
healthy sexually intact adult dogs (Co-PI)
Stephen Oliver

Identification, characterization, and evaluation of
Streptococcus uberis virulence factors

USDA Formula Funds

$ 7,000.00
1% 1/95-9/30/96

$

7,000.00

Efficacy of two novel experimental postmilking teat
disinfectants for the prevention of mastitis in dairy cows
under natural exposure conditions

Famam Companies, Inc.

$ 69,600.00
1995-96

$

3,395.19

Influence of clinical and subclinical mastitis during early
Iodation on reproductive performance of Jersey cows

American Jersey Cattle Association Research
Foundation

$ 6,000.00
1996

Influence of intramammary antibiotic therapy at
on mastitis and lactational performance of heifers
during early lactation

The Upjohn Company

$ 38,250.00
1995-97

$

20,534.00

Evaluation of specific immune responses and protection
by novel streptococcal antigens

Pfizer Company

$108,848.00
4/97-12/98

Robert l. Schattner Foundation

$ 65,000.00
6/97

American Jersey Cattle Association Research
Foundation

$
6,000.00
1996

National Pork Producers

$ 24,500.00
9/01/96-8/31/97

$

10,454.21

USDA 1433 Funds

$ 11,000.00
10/1/95-9/30/96

$

11,000.00

--- .. ------ ... __ ..............

lactation/mastitis research

Hormonal changes associated with clinical mastitis
during early lactation in Jersey cows (Co-PI)

Toxoplasma gondii in swine populations: A comparison
of the percentage of sows and market-weight pigs
infected from the NAHMS, farm management practice
relationships, and economic costs

Sharon Patton

Epidemiology of Toxoplasma gondii in swine
populations: A comparison of the seroprevalence of
Toxoplasma gondii in hogs and market weight pigs in
the NAHMS, farm management pradice relationships,
and economic costs

Patton - Continued

Bart Rohrbach

Randomized clinical trial to evaluate the effed of
vaccination against Leptospira spp to prevent ERU in
horses.

Fort Dodge

$ 27,845.00
5/15/97-8/15/-98

Barry Rouse

Herpes zosterfilization

Smith-Kline Biological

$124,746.00
7/1/90-12/31/04
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Mucosal immunity in control of herpetic infection

National Institute of Allergy and Infectious
Diseases NIH

$728,711.00
1993-97

$

209,616.29

Immunity mechanisms in herpesvirus infections

National Institute
Diseases - NIH

and Infectious

$783,510.00
1995-00

$

254,241.53

Mechanisms of herpetic stromal keratitis

National Eye Institute - NIH

$1,047,093.00
992-97

$

221,919.82

Anticarcinogenic effects of Dexniguldipine-HcL in
hamster

BYK Gulden

$379,283.00
1993-97

$

20,442.60

NNK effects on receptor pathways

National Institute of Health

$599,126.00
994-97

$

134,065.81

Regulation of the proliferative response of pulmonary
neuroendocrine cells to nicotinic agonists

Verum Foundation for Behavior and
Environment

$128,484.00
1/96-12/97

$

42,533.82

National Institute of Health

$506,499.00
7/31/97

$

184,945.48

Development of a bioremediation risk assessment
scheme

US Environmental Protection Agency

$ 54,749.00
9/94-9/97

$

5,443.27

Structure-biodegradability/toxicity relationships of
substituted naphthalenes

Dupont Corporation

$ 40,000.00
6/95-6/97

$

40,000.00

The role of bioavailability in determining
environmentally acceptable endpoints for
bioremediation of polychlorinated biphenyls
(Co-PI)

US Department of Energy

$441,037.00
3/97-2/00

Photo-induced toxicity in Tetrahymena

University of Minnesota

$ 19,063.00
1/94-12/96

$

19,063.00

A. Eric Schultze

Vascular cell injury by toxicants of tall fescue grass
PI)

USDA Formula Funds

$

J.

Role of agouti gene in tumorogenesis

Lockheed Martin

$ 76,710.00
10/01/95-9/30/97

$

41,562.97

Collaborative studies on the cellular and molecular
basis of disease in the scurfy mouse

lockheed Martin

$ 24,000.00
7/29/96-7/28/97

$

21,208.71

Genome analysis program

Lockheed Martin

$ 75,195.00
2/96-9/30/97

$

38,971.91

Histopathologic and clinical pathology analyses of mice
from a colonv containing chromosomal translocations

Lockheed Martin

$ 102,250.00
7/1/95-3/21/98

$

49,181.39

Role of the agouti gene product on tumorogenesis

Lockheed Martin

$ 67,000.00
7/01/95-12/31/96

$

25,720.20

Barry Rouse (continued)

Hildegard Schuller

Transplacental pancreatic carcinogenesis by NNI

Terry Schultz

.I:a

U'I

Erby Wilkinson

5,000.00

t • t t

J. Erby Wilkinson (confined)

A
0

Directed expression of the agouti gene product in
transfenic mice: A potential model for obesity

Glaxo

$ 672,890.00
10/93-9/96

$

77,389.90

Mammalian genetics and development

Lockheed Martin

$ 70,850.00
10/95-9/96

$

21,924.52

Lockheed Martin

$ 41,391.00
10/95-9/96

Mouse
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